apceth Biopharma manufactures cell and gene therapy products for American and Europeanclients through two manufacturing sites in Munich, Germany, certified for GMP manufacturesince 2010. These facilities are fully compliant with all current EU regulations (ATMP regulation(EC) No.1394/2007) and ICH guidelines. The company’s strength lies in its experience andcomprehensive quality management systems allowing the manufacturing and development of awide range of complex cell and gene therapy products. Through this deal, Hitachi Chemical willacquire two state-of-the-art GMP/BSL2 production facilities including 600 m 2 of cleanroom area.

Robert A. Preti, PhD, CEO and President of Hitachi Chemical Advanced Therapeutics Solutions, LLC and General Manager of the Hitachi Chemical Regenerative Medicine Business Sector said:

“The addition of apceth Biopharma to Hitachi Chemical will strengthen our presence in thesecond-largest cell and gene therapy market in the world, and enable us to offer a trulyharmonized global operation, providing our customers with ready access to new markets andmaximizing the value we bring to the industry.”

Christine Guenther, MD, CEO of apceth Biopharma said:

“We are very pleased to become part of Hitachi Chemical. Our combined strengths within Hitachi Chemical will allow us to manufacture complex cell and gene therapies for clients in North America, Asia, and Europe. This will allow us to supply patients around the world with highly needed innovative and high-quality cell and gene therapies.”

“Since 2007, Apceth had been built by a great team and strong support of its shareholders into Europe’s leading independent cell therapy manufacturer. We are very proud that these joint efforts resulted in apceth Biopharma now being chosen as Hitachi Chemical’s hub for celltherapy in Europe.”

This global contract development and manufacturing services platform currently includes twoU.S. facilities, in Allendale, NJ and Mountain View, CA, and a recently opened facility inYokohama, Japan. Construction is underway for a third U.S. facility in Allendale, NJ that willprovide commercial manufacturing capability for products after the opening in the second quarter of 2019. The addition of apceth in Europe to Hitachi Chemical will complement the PCT global servicesplatform’s global footprint to jointly more than 180,000 square feet. All of these facilities will shareharmonized quality and information management systems, accounting for all regional regulatoryrequirements, as well as harmonized manufacturing operations, and technology transferapproaches, designed to ensure a seamless and rapid approach to serving clients globally.

Robert A. Preti, PhD, Chief Executive Officer and President, Hitachi Chemical Advanced Therapeutics SolutionsRobert “Bob” Preti is the co-founder of Hitachi Chemical Advanced Therapeutics Solutions ("HCATS", formerly PCT) and the visionary behind its successful growth and development strategy over much of the last two decades.

Subscribe to our blog for instant updates on challenges and trends in cell therapy development, manufacturing and commercialization.